Recent

% | $
Quotes you view appear here for quick access.

OXiGENE, Inc. Message Board

  • vvvvvvrebel89130 vvvvvvrebel89130 Mar 26, 2014 3:42 PM Flag

    no mention of o/s from transcript

    In terms of next steps, of course we will look forward to a presentation of the full dataset at a scientific meeting later this year, which we expect to include the current (indiscernible) specific details on progression-free survival and objective response rate. In the meantime, we intend to evaluate the necessary next development and regulatory steps for the combination of ZYBRESTAT plus Avastin.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • They probably do not have enough events yet to calculate O/S. From disease progression to death could take at least several months. So I would not expect O/S data until later in the year. The longer we wait might mean good results though not guaranteed. In any case, I would expect talks with EU regulators to be mainly based on the great progression free survival number we just received since other companies have been approved on such data.
      If a large pharma wants to get a bargain price for an acquisition or partnership, they will make a move before O/S data is announced.

 
OXGN
0.6096-0.0099(-1.60%)Feb 5 3:59 PMEST